AN2 Therapeutics, Inc. beat EPS estimates 0% of the time across 2 reported quarters (0 beats, 2 misses), averaging -23.5% versus consensus. Data sourced from SEC EDGAR.
| Quarter | EPS Estimate | EPS Actual | Surprise | Result | Call |
|---|---|---|---|---|---|
| Q2 FY26 | not reported | $-0.18 | not reported | not reported | |
| Q1 FY26 | $-0.23 | $-0.29 | -26.1% | Miss | |
| Q4 FY25 | $-0.24 | $-0.29 | -20.8% | Miss |
Back to ANTX overview · ANTX holders · ANTX KPIs
Data sourced from U.S. SEC EDGAR filings. Not personalized investment advice.